China Biomanufacturing Industry Surpasses 1 Trillion Yuan: A-share Investment Impact

The 2025 Biomanufacturing Conference reported a milestone for China’s biomanufacturing industry, with total scale reaching 1.1 trillion yuan and bio-fermentation products accounting for over 70% of global output (note: exact figures not verified in English-language sources). Despite verification challenges, multiple sources confirm China’s dominant position in the global bio-fermentation industry, producing key products such as enzymes, amino acids, and vitamins. In the A-share market, Asymchem Laboratories (002821.SZ), a leading biopharmaceutical CDMO, has demonstrated strong performance, recording a 28.06% year-to-date increase and a market cap of $31.73 billion. The company recently expanded its Shanghai Fengxian Commercial Manufacturing Base, enhancing its global CDMO capabilities [0]. Investor sentiment towards China’s biotech sector is positive, with analysts framing biomanufacturing as part of “new China” industries (including AI) expected to drive future earnings growth [1]. Regulatory support is also evident, as the Beijing Stock Exchange prioritizes strategic emerging industries like biomedicine for listings [3].

1. The industry’s reported 1 trillion yuan scale signals structural growth, positioning A-share biomanufacturing companies in a favorable global supply chain context.
2. Biopharma CDMOs like Asymchem (002821.SZ) are well-positioned to benefit from increasing global demand, supported by their expanded manufacturing capabilities [0].
3. The “new China” sector classification by analysts [1] highlights biomanufacturing’s role in China’s economic transition, attracting institutional investment from both domestic and international investors—including 90% of U.S. investors surveyed by Morgan Stanley seeking to increase China exposure [2].

• Opportunities
  :
  1. Regulatory support from exchanges (Beijing Stock Exchange, Star Market) for emerging biomanufacturing companies.
  2. China’s dominant global share in bio-fermentation products.
  3. Strong investor interest in “new China” sectors, driving capital inflows.
• Risks
  :
  1. Unverified nature of the 1.1 trillion yuan industry scale and 70% global market share figures from the 2025 Biomanufacturing Conference.
  2. Need for thorough due diligence on individual A-share listed companies to assess their actual exposure to the biomanufacturing sector.
  3. Potential regulatory uncertainties inherent in fast-growing emerging industries.

China’s biomanufacturing industry is a growing segment with global dominance in bio-fermentation, attracting significant investor attention to A-share listed companies. Asymchem Laboratories (002821.SZ) exemplifies strong performance in the biopharma CDMO sub-sector, supported by its expanded manufacturing capabilities [0]. Regulatory support and positive investor sentiment, particularly towards “new China” industries, contribute to the sector’s appeal. However, investors should note the unverified nature of the reported industry scale figures and conduct comprehensive due diligence on individual companies before making investment decisions.